FGFR2 amplification and fusion structural variants have been considered to be relevant tumour drivers owing to the consequential receptor overexpression and constitutive dimerization mediated by oligomerization domains in the fusion partners2,20–22. The gene discussed is FGFR2; the disease is neoplasm.